CN106267052A - A kind of medicine treating infantile acute upper respiratory infection and preparation method thereof - Google Patents
A kind of medicine treating infantile acute upper respiratory infection and preparation method thereof Download PDFInfo
- Publication number
- CN106267052A CN106267052A CN201510296465.0A CN201510296465A CN106267052A CN 106267052 A CN106267052 A CN 106267052A CN 201510296465 A CN201510296465 A CN 201510296465A CN 106267052 A CN106267052 A CN 106267052A
- Authority
- CN
- China
- Prior art keywords
- preparation
- rhizoma
- medicine
- chinese medicine
- qjsm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition treating infantile acute upper respiratory infection, and preparation method thereof.The Chinese medicine composition of the present invention has the most antipyretic, antiinflammatory, the effect such as antibacterial, can be used for treating infantile acute upper respiratory infection.The present invention is that clinic provides a kind of better efficacy, convenient medicine, and by described Chinese medicine composition, pharmaceutically acceptable adjuvant is made, and pharmaceutical preparation is oral liquid, granule, tablet, capsule, drop pill, soft capsule, oral effervescent tablet.
Description
Technical field
The present invention relates to a kind of medicine treating infantile acute upper respiratory infection and preparation method thereof, specifically
Say, relate to the medicine made for raw material with Chinese medicine Rhizoma Cimicifugae, Rhizoma Zingiberis Recens, Rhizoma Belamcandae and Pericarpium Citri Reticulatae, belong to the field of Chinese medicines.
Background technology
Infantile acute upper respiratory infection (child acute upper respiratory infection, CAURI) is children's
The common disease of respiratory system, the most all has generation, especially multiple in Winter-Spring dry season.
Modern study shows, virus infects and antibacterial infection is that infantile acute upper respiratory infection is main pathogenic
Factor, wherein virus and antibacterial infect and account for more than the 95% of acute upper respiratory tract infection, and common causative includes
Respiratory syncytial virus, influenza virus, adenovirus, rhinovirus, parainfluenza virus, coronavirus etc..
The main clinical manifestation of infantile acute upper respiratory infection have heating, aversion to wind and cold, nasal obstruction, watery nasal discharge, sneeze,
Cough, headache, systemic pain etc..Primary disease is with accompanied symptoms person, it is seen that have expectorant, gastral cavity abdominal distention between cough aggravation, larynx
Completely, anorexia, eructating foul odor are felt sick, peaceful, frightened cautious convulsion uncomfortable, irritated etc. of defecating shows.
Infantile acute upper respiratory infection mostly is self-limited disease, and the course of disease is shorter, if but suiting the medicine to the illness the most timely
Treatment, is easily changed into pneumonia, tracheitis, bronchitis, otitis media, meningitis etc., has a strong impact on patient's
Healthy.
Acute upper respiratory tract infection belongs to the cold of the traditional Chinese medical science, typhoid fever category, and children's's cold has " fragile muscle and skin, god
Timidness due to deficiency of QI, it is easy to thoughts and feelings " feature.When defending QI-insufficiency, weakened defensive QI, six evil or epidemic miasma are easily taken advantage of a weak point in opponent's defence
Invasion and attack, enter from mouth and nose or fur, visitor defend in lung, cause defend table regulation mistake department, Wei Yang is held back, Lung Qi obstraction,
Thus cause a series of pathological change, the symptoms such as heating, aversion to wind and cold, nasal obstruction watery nasal discharge, cough occur.Visible
Sick pathogenesis key is lung qi obstruction, and the cause of disease is endogenous cause of ill (deficiency of defensive qi, unit does not closes at mansion, and space between skin and muscles is often dredged) and exopathogenic factor
(six evil or the invasion and attack of epidemic miasma) comprehensive.Children's is " pure-yang constituent ", and cold-evil attacks heat-transformation in table easy entry,
The card of the excessive heat in the interior such as dry pharynx, thirsty, irritated, dry stool dark coloured urine occur, form syndrome of superficies cold and interior heat, treatment is preferably adopted
With relieving the exterior syndrome with drugs of pungent in flavor and warm in nature and heat-clearing and toxic substances removing.
At present effective medicine is still lacked for children's acute upper respiratory infection, mostly take anti symptom treatment, go because of
Treatment and supporting treatment.Fully to have a rest, keep ventilation, good surrounding, pay attention to general nursing, in advance
Anti-complication is main.Antiviral therapy is one of Main Means of current clinical treatment, mainly includes that ucleosides resists
Virus medicine (acyclovir, ribavirin, lamivudine, zidovudine etc.) and non-nucleoside antiviral agents are (dry
Disturb element, amantadine, neuraminidase inhibitor etc.), rapid-action but generally have in various degree bad instead
Should.Bacterial upper respiratory tract infection or viral upper respiratory tract infection secondary bacterial infection person can be selected for antibiotic and control
Treat, but not as recommended by routine medication, if virus infects caused person, not only antibiotic is invalid, also can cause
Body dysbacteriosis, it is necessary to avoid abuse.Height is warm or has febrile convulsion history person, should actively lower the temperature, can be cold with head
Apply, or Metamizole nasal drip, or fever-reducing suppository for children anus filled in, or oral acetaminophen, ibuprofen, Ah
Department woods, nimesulide etc..
Chinese Traditional Medicine uses the method for determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs in terms for the treatment of infantile acute upper respiratory infection, have accumulated
More rich experience, and achieve good clinical efficacy, define a number of Chinese patent medicine, representative
Kind include children's's elytrum heat-clearing granule, child throat and tonsil particles, xiao'er ganmao granules, Ganmaoshu Keli for children,
Wushicha granules etc..
Annual winter-spring season, weather is the most colder and dry, by vile weather, youngsters such as hazes in recent years
The impact of the factors such as virgin poor, the influenza virus constantly variation of body constitution, infantile acute upper respiratory infection wind-cold syndrome
Sickness rate rises year by year.The morbidity of this disease is anxious, easily converts, and hazardness is bigger.It is specifically designed to this disease for the treatment of at present
Western medicine and Chinese patent medicine kind are the shortest, it is difficult to meet clinical demand.
This prescription is by coming from the Sun Simiao Prescriptions Worth Thousand Gold for Emergencies Tang Dynasty it " Cimicifugae Decoction ", and former book is described as: Rhizoma Cimicifugae,
Rhizoma Zingiberis Recens, each 2 liang of Rhizoma Belamcandae, Pericarpium Citri tangerinae 1 liang.Take four tastes, with six liters of water, steam and take two liters, remove slag, point three clothes.
Control children's's laryngalgia, if poison is contained, just obstruction of the pharynx, and main adult discomfort in the throat side.After this prescription be embodied in again the Qing Dynasty
Tan Jinzhang " sincere book " rolls up six they " a thousand pieces of gold Rhizoma Cimicifugae dissipates ", and former book is described as: Rhizoma Cimicifugae 3 money, Rhizoma Belamcandae 3 money, Rhizoma Zingiberis Recens 3
Money, Pericarpium Citri tangerinae 1 money (side of having adds Radix Et Rhizoma Rhei), it is decocted in water for oral dose, cures mainly pyretic toxicity laryngalgia, obstruction of the pharynx.Modern study shows,
Rhizoma Cimicifugae contains the chemical compositions such as triterpene and glycoside thereof, Phenylpropanoid Glycosides class, containing volatile oil, gingerol in Rhizoma Zingiberis Recens
Etc. chemical composition, Rhizoma Belamcandae mainly contains isoflavonoid, Pericarpium Citri Reticulatae mainly contains volatile oil and flavonoid
Composition, these compositions are all one of main active of prescription performance curative effect, but in conventional soak by water process
In often extraction ratio is relatively low or loss is serious, greatly reduce the curative effect of prescription, and children's's clinic of decoction be suitable
Answering property is poor.In order to preferably embody modern Chinese medicine safely, effectively, controlled feature, need to carry out deep
Research work.
In this prescription, Rhizoma Cimicifugae is ranunculaceae plant C.heracleifolia Cimicifuga heraclei folia Kom., emerging
Peace Rhizoma Cimicifugae Cimicifuga dahurica (Turcz.) Maxim or the dry root of Rhizoma Cimicifugae Cimicifuga foetida L.
Stem.Rhizoma Cimicifugae has expelling pathogenic wind from the body surface, heat-clearing and toxic substances removing, rises the effect lifting yang-energy.Rhizoma Cimicifugae is kind controls YIN YANG toxin syndrome, plays clear
Throat, expelling pathogenic factors from muscles are delivered, the effect of removing toxic substances and promoting pus discharge, can detoxify, clearing throat and evacuation of pus blood.Rhizoma Zingiberis Recens is Zingiberaceae Rhizoma Zingiberis Recens
The fresh rhizome of platymiscium Rhizoma Zingiberis Recens (Zingiber officinale Rosc.), belongs to pungent and warm medicine for relieving the exterior syndrome.Return lung,
Spleen, stomach warp, be used for anemofrigid cold, has relieving the exterior syndrome by diaphoresis, expelling wind and cold effect.Rhizoma Belamcandae is Iridaceae
Plant Rhizoma Belamcandae Belamcanda chinensis (L.) DC or Rhizoma Belamcandae Iris tectorum Maxim. is dried
Rhizome, tool heat-clearing and toxic substances removing, sore-throat relieving expectorant, the function of scattered blood detumescence, it is adaptable to laryngopharynx swelling and pain, productive cough gas
The disease such as breathe heavily, for treating the key medicine of sore throat pharyngalgia.Pericarpium Citri Reticulatae is rutaceae orange (Citrus reticulate
And the dry mature skin of variety, Blaneo) there is regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm effect.According to
Analysis above, cures mainly the function of medicine of the present invention and is summarized as: warming YANG for relieving the exterior syndrome, heat-clearing and toxic substances removing, be used for
Infantile acute upper respiratory infection wind-cold syndrome, disease sees the cough of fever with chills, laryngopharynx swelling and pain, abundant expectoration, gastral cavity abdomen
Distension etc..
To sum up, infantile acute upper respiratory infection is department of pediatrics common disease, and current chemical medicine treatment spininess is to outside sick
Source is treated, and ignores children's's deficiency of defensive qi, and unit does not closes at mansion, and the endogenous cause of ill that space between skin and muscles is often dredged, curative effect is not the best enough.
This prescription comes from classical ancient books, determined curative effect, but preparation method and key agents chemical composition and pharmacological action thereof
Misfit, by the work of the present invention, more preferable curative effect will be played clinically for this prescription and create conditions.
Summary of the invention
Technical scheme to be solved by this invention is to provide a kind of medicine treating infantile acute upper respiratory infection
And preparation method thereof.
The present invention provides a kind of Chinese medicine composition treating infantile acute upper respiratory infection, it is characterised in that institute
The weight proportion stating raw material is:
Rhizoma Cimicifugae 2 parts, 2 parts of Rhizoma Zingiberis Recens, Rhizoma Belamcandae 2 parts, Pericarpium Citri Reticulatae 1 part, or
Rhizoma Cimicifugae 3 parts, 3 parts of Rhizoma Zingiberis Recens, Rhizoma Belamcandae 3 parts, Pericarpium Citri Reticulatae 1 part.
The preparation method of described Chinese medicine composition, said method comprising the steps of:
1) taking prescription consumption and weigh medical material, use 10-20 times of water extraction volatile oil 1-5 hour, volatile oil separates
After, standby；
2) control step 1 gained Aqueous extracts temperature, for 50-75 DEG C, to be evaporated to relative density 1.10～1.30,
Standby；
3) continue to add 6-20 times of 10%-95% alcohol reflux 1-3 time by step 1 gained medicinal residues, carry every time
Taking time 1-3h, concentrating under reduced pressure gained extracting solution, temperature controls as 50-75 DEG C, to relative density 1.10～1.30,
Standby；
4) by step 2 and step 3 gained concentrated solution mix homogeneously；
5) it is mixed and stirred for uniformly, obtaining Chinese medicine composition by step 1 gained volatile oil and step 4 gained thick paste
Thing.
Described Chinese medicine composition is used for the application treating in the medicine of infantile acute upper respiratory infection in preparation.
The present invention also provides for a kind of medicine treating infantile acute upper respiratory infection, this medicine include described in
Drug composition, and pharmaceutically acceptable adjuvant.
In the preparation of medicine of the present invention, dosage form is oral liquid, granule, tablet, capsule, drop pill
Agent, soft capsule, oral effervescent tablet.
The preparation method of described medicine, this preparation method includes: by described Chinese medicine composition with described pharmaceutically
Acceptable adjuvant mixes.
The preparation method of medicine of the present invention also includes the conventional method using pharmaceutical field, uses the medicinal load of routine
Body, prepares the required preparation being administered by all means.For example with conventional method by 4) extractum is uniform
After mixing, the carrier conventional with on any one or more than one pharmaceuticss or adjuvant mix, and then make various
Required dosage form.Described carrier or adjuvant such as excipient, filler, binding agent, diluent, lubricant,
Wetting agent, disintegrating agent, surfactant, solubilizing agent, emulsifying agent, defoamer, preservative, sweeting agent, virtue
Pastil etc..Concrete, described carrier or adjuvant such as starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl first
Base cellulose, low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, Polyethylene Glycol, tristearin
Acid magnesium, micropowder silica gel, glucose, mannitol, xylitol, glycine, citric acid, fumaric acid, tartaric acid,
Malic acid, protein sugar, saccharin sodium, apple essence, flavoring pineapple essence, flavoring orange essence, Pulvis Talci, solubility are formed sediment
Powder, Stepanol MG etc..
It is a further object of the present invention to provide medicine of the present invention in treatment infantile acute upper respiratory infection and disease
Application in terms of the diseases such as the viral pneumonia that poison infection causes.The medicine of the present invention has antipyretic, antiinflammatory, disease-resistant
The effect such as malicious, antibacterial, can be used for treating infantile acute upper respiratory infection.
Medicine of the present invention have the beneficial effect that it as a kind of medicine, not only have the most antipyretic, antiinflammatory,
Antiviral, antibacterial etc. acts on, and can effectively treat infantile acute upper respiratory infection.And the preparation side of the present invention
Ancient books is recorded by method and modern study report combines, and carries out process rationality confirmation by pharmacodynamics, and can
Make various dosage form as required, thus provide convenient, more efficient for clinic, quality is more controllable
Modern Chinese medicine, brings more clinical Benefit for patient, and creates good social benefit.
Pharmacodynamics test
Treat or the effect of preventing child acute upper respiratory tract infection in preparation in order to the present invention is better described, if
Count and be scheduled that following pharmacodynamics test.
1, test reagent and animal
The pharmacology sample that QJSM-1: this prescription prepares according to ancient books record method.Sepia extractum, 5.12g is raw
Medicine/g extractum, lot number 140620.
The pharmacology sample that QJSM-2: this prescription prepares according to embodiment 1.Sepia extractum, 3.25g crude drug/g
Extractum, lot number 140621.
Merrill Lynch's (ibuprofen suspension), Shanghai pharmaceutical Co. Ltd of Johnson & Johnson produces, lot number: 141012015,
20mg/ml。
Indometacin: the Xiamen pharmaceutical factory of traditional Chinese medicine produces, lot number: 20140903.
Cefuroxime Sodium: Shenzhen Xin Litai pharmaceutical Co. Ltd produces, lot number: 1211721.
SD rat, SPF level, male, some, by Beijing Vital River Experimental Animals Technology Co., Ltd. (perhaps
Can the number of card: SCXK (capital) 2012-0001), body weight is 40-60g, and week old is 3 weeks.
ICR kind mice, male and female half and half, the quality certification number: Institute of Radiation Medicine, Chinese Academy of Medical Sciences.Qualified
Card number: SCXK (Tianjin) 2005-0001.
SD kind rat, male and female half and half, Beijing Vital River Experimental Animals Technology Co., Ltd., the quality certification number:
SCXK (capital) 2007-0001.
Endotoxin, Sigma, lot number: 109K4075.
Ammonia, Tianjin Cheng Bao Trade Co., Ltd. produces, analytical pure, lot number: 20071121.
2, experimental technique and interpretation of result
The impact of the heating functioin that 2.1 induced by endotoxins cause
Select SD kind Immature rat, male, 70, body weight 40-60g.Animal adapts to 3 days.Survey before test
Amount anus temperature, makes rat custom anus temperature measure operation and by measuring anus temperature result random packet, is divided into matched group, mould
Type group, positive drug group, QJSM quadrat sampling product 1 (high and low) group, QJSM quadrat sampling product 2 (high and low) group.It is administered
After lumbar injection freshly prepared escherichia coli endotoxin solution 50 μ g/kg at once, cause Bacteria infective fever,
Matched group gives normal saline.In be administered before and pyrogenicity after 1,2,3,4,5,6 hours, respectively survey anus temperature.
The anus temperature of each administration group rat changes average compare with the anus temperature change average of model group rats, unite
T inspection learned by meter.
Table 1 QJSM side induced by endotoxin causes the impact (respectively organizing rat temperature after modeling) of rat fever
Matched group compares with model group:***p<0.001；Administration group compares with model group:#p<0.05##p<0.01###p<0.001
Experimental data shows, sample QJSM-1 and QJSM-2 all demonstrates good cooling effect after being administered, its
Middle sample QJSM-1 is administered significant cooling effect for latter 3 hours, QJSM-2 be administered after 3,4,5,6 hours all
Having a significant cooling effect, therefore QJSM-2 compares the cooling effect of QJSM-1 and becomes apparent from.
2.2 pairs of protective effects infecting S. aureus L-forms mice
Prepared by bacterium solution: by S. aureus Inoculate in blood dish, cultivates 20h for 37 DEG C, then by this bacterium secondary
Pass on, cultivate 20h, with the viable count of turbidimetry for Determination experimental infection, be diluted to 10 with 5% yeast mixture8Individual bacterium
The bacterial suspension of/ml concentration is standby.
Select ICR kind mice, body weight 18-22g, random packet, often group 10, male and female half and half.By table 2
Shown in dosage ig be administered, QJSM-2 every day 1 time, continuous 5 days, matched group gavage gave the distillation of same volume
Water；Comparison medicine Cefuroxime Sodium was administered in the 5th day.After last is administered, every golden yellow Portugal of mouse peritoneal injection
Grape coccus (108Individual bacterium/ml) 0.5ml (determining the dead amount of bacteria of animal 90%-100% through trial test), respectively
Medicine group successive administration 3 days again (scheme for being administered 7 days, because surviving animals is in good condition after 3 days, therefore stopping
It is administered) and observed and recorded each group mouse survival number and time-to-live in 7 days.
Table 2 QJSM-2 protective effect to In vivo infection staphylococcus aureus mice
* p < 0.05 * * p < 0.01 * * * p < 0.001 is compared with matched group
Experimental data shows, QJSM-2 can dramatically increase mouse survival number, it is possible to significantly extend the average of animal
Time-to-live, show that QJSM-2 has significant protective effect to the mice infecting staphylococcus aureus.
3. the protective effect of pair In vivo infection streptococcus pneumoniae mice
Prepared by bacterium solution: be inoculated in by streptococcus pneumoniae in blood dish, cultivates 20h, then is passed on by this bacterium secondary for 37 DEG C,
After cultivation 20h, normal saline centrifuge washing 3 times, with the viable count of turbidimetry for Determination experimental infection, uses 5% ferment
It is standby that mother solution is diluted to certain density bacterial suspension.
Select ICR kind mice, body weight 20 ± 2g, random packet, often group 10, male and female half and half.By table 3
Shown in dosage ig be administered, QJSM-2 every day 1 time, continuous 5 days；Matched group gives the distilled water of same volume；
Comparison medicine Cefuroxime Sodium was administered in the 5th day.After last is administered, every mouse peritoneal injection streptococcus pneumoniae
(1×108Individual bacterium/ml) 0.5ml, each medicine group successive administration 7 days again, each group mouse survival number in recording 7
And the time-to-live.
Table 3 QJSM-2 protective effect to In vivo infection streptococcus pneumoniae mice
* p < 0.05***p < 0.001 is compared with matched group
Experimental data shows, QJSM-2 is remarkably improved the survival number of elements of In vivo infection streptococcus pneumoniae mice,
And mice mean survival time can be obviously prolonged, show have certain protection to make to the mice of streptococcus pneumoniae infection
With.
4, the impact on acute pharyngitis rat model
SD rat 70 is selected in test, is randomly divided into 7 groups, often group 10, male and female half and half.By table 4 institute
Showing that dosage ig respectively is administered, continuous 6 days, matched group and model group gavage gave the distilled water of same volume.First three
It is administered once daily, in be administered the 4th day to the 6th day, in addition to matched group, each group rat is respectively administered morning and afternoon
Once (it is administered volume half, i.e. each dosage halves, but every TDD is constant), and after being administered
Within 30 minutes, spray into 25% ammonia 70 μ L with laryngeal spray towards each group of rat throat, even spray three times.
In the 7th day 20% urethane anesthetized rat of test, abdominal aortic blood 0.9ml, it is equipped with 3.8% Chinese holly
In the test tube of rafter acid sodium 0.1ml, it is centrifuged 10min separated plasma with 3000r/min；Take blood plasma 0.20ml, add
Distilled water 3.6ml, 10mol/l acetic acid 0.04m1 (1% acetum 0.1ml), is sufficiently mixed and is placed on 4 DEG C of ice
10min in case, then it is centrifuged 10min (3000r/min), abandoning supernatant, the i.e. euglobulin of white precipitate adds
The borate buffer 0.2ml of pH9, stirs molten 1min gently, puts in 37 DEG C of water-baths, then adds 25mmol/L chlorine
Change calcium solution 0.2ml, after euglobulin solidifies, timing immediately. every l0min, observe once, until solidifying
Block is completely dissolved, and is euglobulin lysis time, during the euglobulin lysis of fibrinolysis vigor=10000/
Between.
Table 4 QJSM-2 is on acute pharyngitis rat model euglobulin lysis time and the impact of the vigor of dissolving
* p < 0.05**p < 0.01***p < 0.001 is compared with model group
Experimental data shows, model group rats euglobulin lysis time is obviously prolonged, and QJSM-2 can be the most aobvious
Write and reduce euglobulin lysis time, increase euglobulin lysis vigor, show that QJSM-2 can remarkably promote ammonia
Water induced Acute pharyngitis rat euglobulin lysis.
5, antiinflammatory action
ICR kind mice is selected in test, male, body weight 18-22g.It is randomly divided into 6 groups, often group 10, respectively
Medicine group dosage ig as shown in table 5 is administered, every day 1 time, for three days on end；Matched group gives same volume simultaneously and steams
Distilled water.Last is administered latter 40 minutes, tail vein injection Evans blue solution (1%) 0.05ml/, abdomen simultaneously
Chamber injection glacial acetic acid solution (0.67%) 0.2ml/ is only.After 20 minutes, de-neck puts to death animal, with 5ml physiology salt
Water rinses abdominal cavity, collects eluent, and 2500 revs/min are centrifuged 10 minutes, supernatant SUNRISE microplate reader
Colorimetric at wavelength 580nm, measures optical density (OD value).
Table 5 QJSM-2 impact on mice capillary permeability
* p < 0.05 * * P < 0.01 * * * p < 0.001 is compared with matched group
Experimental data shows, QJSM-2 each dosage group OD value compares with matched group OD value and all significantly reduces,
Show that this medicine can significantly inhibit the mice capillary permeability increase that acetic acid causes, have significant antiinflammatory action.
Detailed description of the invention
The preparation of embodiment 1 QJSM extractum
Taking Rhizoma Cimicifugae 2kg, Rhizoma Zingiberis Recens 2kg, Rhizoma Belamcandae 2kg, Pericarpium Citri Reticulatae 1kg, add 10 times amount water, vapor distillation carries
Take volatile oil 3 hours, collect volatile oil standby；Filtering, at filtrate liquid 60 DEG C, decompression and solvent recovery is to relatively
Density 1.20, standby；Filtering residue adds 50% alcohol reflux 2 times, and each quantity of solvent is 10 times amount, extracts
Time is 1.5 hours, filters, and filtrate merges, and at 60 DEG C, decompression and solvent recovery is to relative density 1.20；It is standby,
The volatile oil being previously obtained and water extracting liquid, ethanol extraction concentrated solution are merged, is QJSM extractum.
The preparation of embodiment 2 QJSM extractum
Taking Rhizoma Cimicifugae 3kg, Rhizoma Zingiberis Recens 3kg, Rhizoma Belamcandae 3kg, Pericarpium Citri Reticulatae 1kg, add 20 times amount water, vapor distillation carries
Take volatile oil 1 hour, collect volatile oil standby；Filtering, at filtrate liquid 75 DEG C, decompression and solvent recovery is to relatively
Density 1.15, standby；Filtering residue adds 30% alcohol reflux 1 time, and quantity of solvent is 20 times amount, extraction time
Being 2 hours, filter, filtrate merges, and at 65 DEG C, decompression and solvent recovery is to relative density 1.15, standby；By front
Volatile oil and water extracting liquid, ethanol extraction concentrated solution that face obtains merge, and are QJSM extractum.
The preparation of embodiment 3 QJSM extractum
Taking Rhizoma Cimicifugae 2kg, Rhizoma Zingiberis Recens 2kg, Rhizoma Belamcandae 2kg, Pericarpium Citri Reticulatae 1kg, add 15 times amount water, vapor distillation carries
Take volatile oil 2 hours, collect volatile oil standby；Filtering, at filtrate liquid 65 DEG C, decompression and solvent recovery is to relatively
Density 1.18, standby；Filtering residue adds 10% alcohol reflux 1 time, and quantity of solvent is 15 times amount, extraction time
Being 3 hours, filter, filtrate merges, and at 60 DEG C, decompression and solvent recovery is to relative density 1.18, standby；By front
Volatile oil and water extracting liquid, ethanol extraction concentrated solution that face obtains merge, and are QJSM extractum.
The preparation of embodiment 4 QJSM extractum
Taking Rhizoma Cimicifugae 3kg, Rhizoma Zingiberis Recens 3kg, Rhizoma Belamcandae 3kg, Pericarpium Citri Reticulatae 1kg, add 18 times amount water, vapor distillation carries
Take volatile oil 4 hours, collect volatile oil standby；Filtering, at filtrate liquid 60 DEG C, decompression and solvent recovery is to relatively
Density 1.22, standby；Filtering residue adds 70% alcohol reflux 2 times, and quantity of solvent is 15 times amount, extraction time
Being 1 hour, filter, filtrate merges, and at 55 DEG C, decompression and solvent recovery is to relative density 1.22, standby；Will
The volatile oil being previously obtained and water extracting liquid, ethanol extraction concentrated solution merge, and are QJSM extractum.
The preparation of embodiment 5 QJSM extractum
Taking Rhizoma Cimicifugae 2kg, Rhizoma Zingiberis Recens 2kg, Rhizoma Belamcandae 2kg, Pericarpium Citri Reticulatae 1kg, add 12 times amount water, vapor distillation carries
Take volatile oil 5 hours, collect volatile oil standby；Filtering, at filtrate liquid 55 DEG C, decompression and solvent recovery is to relatively
Density 1.25, standby；Filtering residue adds 95% alcohol reflux 1 time, and quantity of solvent is 18 times amount, extraction time
Being 2.5 hours, filter, filtrate merges, and at 50 DEG C, decompression and solvent recovery is to relative density 1.25, standby；Will
The volatile oil being previously obtained and water extracting liquid, ethanol extraction concentrated solution merge, and are QJSM extractum.
The preparation of embodiment 6 QJSM extractum
Taking Rhizoma Cimicifugae 3kg, Rhizoma Zingiberis Recens 3kg, Rhizoma Belamcandae 3kg, Pericarpium Citri Reticulatae 1kg, add 16 times amount water, vapor distillation carries
Take volatile oil 3 hours, collect volatile oil standby；Filtering, at filtrate liquid 50 DEG C, decompression and solvent recovery is to relatively
Density 1.30, standby；Filtering residue adds 10% alcohol reflux 3 times, and quantity of solvent is 6 times amount, extraction time
Being 1 hour, filter, filtrate merges, and at 70 DEG C, decompression and solvent recovery is to relative density 1.16, standby；By front
Volatile oil and water extracting liquid, ethanol extraction concentrated solution that face obtains merge, and are QJSM extractum.
The preparation of embodiment 7 QJSM oral liquid
QJSM extractum used by Example 1, takes QJSM extractum 260g, xylitol 20g, sorbic acid
20g, mix homogeneously, it is diluted with water to 1000mL, filters, every bottle of 10mL carries out fill, i.e. prepares and contains
2 parts of Rhizoma Cimicifugaes, 2 portions of Rhizoma Zingiberis Recenss, 2 parts of Rhizoma Belamcandae and the oral liquid of 1 part of Pericarpium Citri Reticulatae.
The preparation of embodiment 8 QJSM capsule
With the QJSM extractum used by embodiment 2, take QJSM extractum 14g and starch 40g, mix homogeneously,
Using 85% alcohol granulation, 60 DEG C are dried, and granulate is encapsulated, i.e. prepare containing 3 parts of Rhizoma Cimicifugaes, 3 portions of Rhizoma Zingiberis Recenss,
The medicine of the capsule formulation of 3 parts of Rhizoma Belamcandae and 1 part of Pericarpium Citri Reticulatae.
The preparation of embodiment 9 QJSM tablet
With the QJSM extractum used by embodiment 3, take QJSM extractum 8g and sucrose 40g, mix homogeneously,
Pelletizing, 60 DEG C are dried, by prepared granule through further tabletting, i.e. prepare containing 2 parts of Rhizoma Cimicifugaes, 2 portions of Rhizoma Zingiberis Recenss,
The medicine of the Tabules of 2 parts of Rhizoma Belamcandae and 1 part of Pericarpium Citri Reticulatae.
The preparation of embodiment 10 QJSM effervescent tablet
Polyethylene Glycol (PEG6000) 10g heating in water bath is melted, adds 36g sodium bicarbonate mix homogeneously,
Cooling crush crosses 80 mesh sieves；The QJSM extractum that embodiment 4 is obtained, drying under reduced pressure, obtain dried cream powder,
Take dry cream 10g, lactose 20g and citric acid 32g, cross 80 mesh sieve mixings；Above powder is mixed, with 10%
Starch slurry is pelletized, and less than 60 DEG C are dried, granulate, magnesium stearate 1g, mix homogeneously, tabletting, i.e. prepares and contains
There is the medicine of the effervescent tablet preparation formulation of 3 parts of Rhizoma Cimicifugaes, 3 portions of Rhizoma Zingiberis Recenss, 3 parts of Rhizoma Belamcandae and 1 part of Pericarpium Citri Reticulatae.
The preparation of embodiment 11 QJSM drop pill
Do with the firing association's flavone used by embodiment 5, take QJSM extractum 20g, mix homogeneously, add 40g and melt
In the polyethylene glycol 6000 melted, stir, be incubated and pour in drop pill device, with 30d/min under 90 DEG C of states
Speed of dripping instill in the liquid paraffin of 10 DEG C, make drop pill, i.e. prepare containing 2 parts of Rhizoma Cimicifugaes, 2 portions of Rhizoma Zingiberis Recenss, 2
The medicine of the drops of part Rhizoma Belamcandae and 1 part of Pericarpium Citri Reticulatae.
The preparation of embodiment 12 QJSM soft capsule
With the QJSM extractum used by embodiment 6, take QJSM extractum 6g and vegetable oil 60g, mixing, use
Capsule casing material made by gelatin, is pressed into soft capsule, i.e. prepare containing 3 parts of Rhizoma Cimicifugaes, 3 portions of Rhizoma Zingiberis Recenss, 3 parts of Rhizoma Belamcandae and
The medicine of the soft capsule dosage form of 1 part of Pericarpium Citri Reticulatae.
The preparation of embodiment 13 QJSM granule
With the QJSM extractum used by embodiment 6, take QJSM extractum 8g and sucrose 40g, mix homogeneously,
Pelletizing as binding agent with 70% ethanol, 50 DEG C are dried, i.e. prepare containing 3 parts of Rhizoma Cimicifugaes, 3 portions of Rhizoma Zingiberis Recenss, 3 parts
The medicine of the bead dosage form of Rhizoma Belamcandae and 1 part of Pericarpium Citri Reticulatae.
Claims (6)
1. the Chinese medicine composition treating infantile acute upper respiratory infection, it is characterised in that the weight of described raw material
Amount proportioning is:
Rhizoma Cimicifugae 2 parts, 2 parts of Rhizoma Zingiberis Recens, Rhizoma Belamcandae 2 parts, Pericarpium Citri Reticulatae 1 part, or
Rhizoma Cimicifugae 3 parts, 3 parts of Rhizoma Zingiberis Recens, Rhizoma Belamcandae 3 parts, Pericarpium Citri Reticulatae 1 part.
2. the preparation method of Chinese medicine composition described in claim 1, said method comprising the steps of:
1) taking prescription consumption and weigh medical material, use 10-20 times of water extraction volatile oil 1-5 hour, volatile oil divides
From rear, standby；
2) control step 1 gained Aqueous extracts temperature, for 50-75 DEG C, to be evaporated to relative density 1.10～1.30,
Standby；
3) continue to add 6-20 times of 10%-95% alcohol reflux 1-3 time by step 1 gained medicinal residues, carry every time
Taking time 1-3h, concentrating under reduced pressure gained extracting solution, temperature controls as 50-75 DEG C, to relative density 1.10～1.30,
Standby；
4) by step 2 and step 3 gained concentrated solution mix homogeneously；
5) it is mixed and stirred for uniformly, obtaining Chinese medicine composition by step 1 gained volatile oil and step 4 gained thick paste
Thing.
3. it is used for treating on children's acute breathing according to the Chinese medicine composition described in any one of claim 1-2 in preparation
Application in the medicine that road infects.
4. treating a medicine for infantile acute upper respiratory infection, this medicine includes any one of claim 1-3 institute
The Chinese medicine composition stated, and pharmaceutically acceptable adjuvant.
5. containing the preparation of medicine described in claim 4, wherein, the preparation of described medicine be oral liquid, granule,
Tablet, capsule, drop pill, soft capsule, oral effervescent tablet.
6., according to the preparation method of the medicine described in any one of claim 4-5, this preparation method includes: by described
Chinese medicine composition mixes with described pharmaceutically acceptable adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510296465.0A CN106267052A (en) | 2015-06-03 | 2015-06-03 | A kind of medicine treating infantile acute upper respiratory infection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510296465.0A CN106267052A (en) | 2015-06-03 | 2015-06-03 | A kind of medicine treating infantile acute upper respiratory infection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106267052A true CN106267052A (en) | 2017-01-04 |
Family
ID=57656174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510296465.0A Pending CN106267052A (en) | 2015-06-03 | 2015-06-03 | A kind of medicine treating infantile acute upper respiratory infection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106267052A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107281418A (en) * | 2017-06-21 | 2017-10-24 | 成都中医药大学 | A kind of food, functional food or pharmaceutical composition and its production and use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101485730A (en) * | 2008-01-16 | 2009-07-22 | 北京天科仁祥医药科技有限公司 | Medicament composition for treating children's exogenous fever and preparation method thereof |
| CN101978983A (en) * | 2010-11-16 | 2011-02-23 | 广州固志医药科技有限公司 | Chinese medicinal composition for treating acute upper respiratory infection and preparation method thereof |
| CN103127405A (en) * | 2012-12-20 | 2013-06-05 | 刘登富 | Chinese materia medica preparation for treating child acute upper respiratory infection |
-
2015
- 2015-06-03 CN CN201510296465.0A patent/CN106267052A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101485730A (en) * | 2008-01-16 | 2009-07-22 | 北京天科仁祥医药科技有限公司 | Medicament composition for treating children's exogenous fever and preparation method thereof |
| CN101978983A (en) * | 2010-11-16 | 2011-02-23 | 广州固志医药科技有限公司 | Chinese medicinal composition for treating acute upper respiratory infection and preparation method thereof |
| CN103127405A (en) * | 2012-12-20 | 2013-06-05 | 刘登富 | Chinese materia medica preparation for treating child acute upper respiratory infection |
Non-Patent Citations (1)
| Title |
|---|
| 俞玫红 等: ""午时茶中成药在急性上呼吸道感染疾病中的应用"", 《中国误诊学杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107281418A (en) * | 2017-06-21 | 2017-10-24 | 成都中医药大学 | A kind of food, functional food or pharmaceutical composition and its production and use |
| CN107281418B (en) * | 2017-06-21 | 2021-01-15 | 成都中医药大学 | Pharmaceutical composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101049424B (en) | Medication for treating infection in respiratory system | |
| CN102302721B (en) | Pharmaceutical composition for treating bronchitis as well as preparation method and use thereof | |
| CN102805776B (en) | Traditional Chinese medicine composition and preparation method of traditional Chinese medicine composition | |
| CN101209287A (en) | Heat-clearing and detoxication antiphlogistic detumescence Chinese medicinal composition and preparation thereof | |
| CN103735679B (en) | Chinese medicine composition of a kind of diminishing inflammation and clearing pharynx and preparation method thereof | |
| CN105497133A (en) | Periplaneta Americana medicine composition for treating pharyngitis and tonsillitis and preparation method thereof | |
| CN106267052A (en) | A kind of medicine treating infantile acute upper respiratory infection and preparation method thereof | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN103989762B (en) | Chinese medicine composition of internal organs relieving cough and resolving phlegm and preparation method thereof is rushed down in a kind of heat clearing away | |
| CN102670855B (en) | Traditional Chinese medicine compound for treating postnasal drip syndrome and preparation method for traditional Chinese medicine compound | |
| CN104707126A (en) | Medicament for treating streptococcus pneumonia infected pneumonia and preparation method thereof | |
| CN104225405A (en) | Chinese medicinal buccal tablet for treating respiratory tract infection and preparation method | |
| CN105617319A (en) | Preparation method of traditional Chinese medicine composition for treating acute cholecystitis | |
| CN101829185B (en) | Medicinal composition for resisting influenza virus | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN103656267B (en) | A kind of Chinese medicine composition that is used for the treatment of pig blue-ear disease and its preparation method and application | |
| CN102349956A (en) | Compound extract for moisturizeing pathogenic dryness and relieving itching and preparation thereof | |
| CN109820826B (en) | Anti-inflammatory traditional Chinese medicine granules and preparation method thereof | |
| CN102233026B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN101069703A (en) | Medicine for treating acute, chronic pharyngitis, acute, chronic tonsillitis and preparing method | |
| CN1245204C (en) | Medicine for curing acute pharyngitis and its preparing method | |
| CN105395662A (en) | Traditional Chinese medicine composition for treating bacillary dysentery and preparing method and quality control method thereof | |
| CN106138259A (en) | A kind of Chinese medicine composition treating anemopyretic cold and preparation method thereof | |
| CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes | |
| CN115317569A (en) | Dendrobium yin-nourishing qi-tonifying blood-sugar-reducing pill and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |